ストックスクリーナーアプリを入手
2.52
1.61%
0.04
前日終値:
$2.48
開ける：
$2.43
24時間の取引高:
96,524
Relative Volume:
1.11
時価総額：
$177.36M
収益：
-
当期純損益:
$-29.64M
株価収益率:
-5.8605
EPS:
-0.43
ネットキャッシュフロー:
$-39.43M
1週間 パフォーマンス:
-1.56%
1か月 パフォーマンス:
-11.89%
6か月 パフォーマンス:
+10.53%
1年 パフォーマンス:
-13.10%
1日の値動き範囲:
$2.30
$2.525
1週間の範囲:
$2.30
$2.60
52週間の値動き範囲:
$1.75
$4.3866
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
DRTS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
2.52 | 177.36M | 0 | -29.64M | -39.43M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-15 | 開始されました | Citigroup | Buy |
| 2023-04-24 | 開始されました | H.C. Wainwright | Buy |
| 2022-04-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-04-08 | 開始されました | Piper Sandler | Overweight |
| 2022-04-04 | 開始されました | Citigroup | Buy |
Alpha Tau Medical Ltd (DRTS) 最新ニュース
Alpha Tau Medical (NASDAQ:DRTSW) Shares Down 7.4% – Time to Sell? - Defense World
Alpha Tau Receives Fda Approval to Initiate A Trial for Patients with Recurrent Glioblastoma - MarketScreener
Alpha Tau receives FDA approval to start trial for patients with recurrent GBM - TipRanks
Alpha Tau Receives FDA Approval To Initiate A Trial For Patients With Recurrent Glioblastoma - MarketScreener
Alpha Tau Medical Receives FDA Approval for Glioblastoma Trial - TipRanks
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma - GlobeNewswire
Major FDA Approval: Alpha Tau's Revolutionary Brain Cancer Treatment Advances to Human Trials - Stock Titan
Analyzing Vivos Therapeutics (NASDAQ:VVOS) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
Comprehensive Insights of the Global Vulvar Cancer Market: Key Drivers, Trends, Growth Opportunities, and F... - WhaTech
Alpha Emitter Market Demand, Growth and Future Scope 2025-2032 | - openPR
HC Wainwright Forecasts Lower Earnings for Alpha Tau Medical - Defense World
Pancreatic Cancer Clinical Pipeline | 290+ Companies Advancing the Future of Treatment - openPR.com
Alpha Tau Medical’s (DRTS) Buy Rating Reaffirmed at HC Wainwright - Defense World
Q1 Virtual Investor Summit: On-Demand Presentations Now Live - The Globe and Mail
H.C. Wainwright maintains Buy on Alpha Tau stock, $9 target - Investing.com
H.C. Wainwright maintains Buy on Alpha Tau stock, $9 target By Investing.com - Investing.com UK
Promising Clinical and Regulatory Milestones Drive Buy Rating for Alpha Tau Medical Ltd. - TipRanks
Alpha Tau Medical Faces Uncertain Future Amid Clinical Trial Challenges - TipRanks
Alpha Tau Medical Reports 2024 Earnings and Clinical Progress - TipRanks
Alpha Tau Medical (NASDAQ:DRTSW) Trading Down 2.7% – Time to Sell? - Defense World
Alpha Tau Medical Reports 2024 Financial Results and Advances in Cancer Therapy Trials - TipRanks
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Alpha Tau's Cancer Therapy Achieves 100% Disease Control Rate in Latest Trials - StockTitan
Alpha Emitter Market to Witness Remarkable Growth with Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd - openPR
U.S. Brain Tumor Market Size & Share | Industry Report 2034 - Grand View Research
March 2025 Penny Stocks To Consider For Growth - Simply Wall St
Alpha Tau Medical to Showcase Alpha DaRT at March Investor Conferences - TipRanks
Alpha Tau to Participate in March Investor Conferences - The Manila Times
Sonodynamic Therapy Shows Promise for Glioblastoma Treatment - Targeted Oncology
Alpha Tau Achieves MDSAP Certification, Boosting Global Expansion Efforts - TipRanks
Alpha Tau Medical Gets Medical Device Single Audit Program Certification -February 24, 2025 at 10:37 am EST - Marketscreener.com
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification - The Manila Times
Can This New Medical Certification Transform Alpha Tau's Cancer Treatment Rollout? - StockTitan
Locally Advanced Pancreatic Cancer Market to Reach New Heights - openPR
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update - MarketBeat
Alpha Tau Announces FDA Approval of IDE Supplement to - GlobeNewswire
Alpha Tau Medical Gets FDA Approval to Expand DaRT Study in Pancreatic Cancer - Marketscreener.com
Alpha Tau Medical Ltd. Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT®? to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease - Marketscreener.com
Alpha Tau Gains FDA Approval to Expand Pancreatic Cancer Trial - TipRanks
Major Clinical Trial Expansion: Alpha Tau Doubles Down on Revolutionary Pancreatic Cancer Treatment - StockTitan
Alpha Emitter Market Projected To Witness Massive Growth, - openPR
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day - GlobeNewswire
Alpha Tau Medical Reports Promising Interim Data and Regulatory Milestones in Cancer Trials - TipRanks
Alpha Tau shares interim data across multiple clinical trials at R&D Update Day - TipRanks
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials -January 27, 2025 at 09:02 am EST - Marketscreener.com
Alpha Tau's Cancer Therapy Shows Breakthrough Results in Multiple Clinical Trials - StockTitan
Alpha Tau Medical (NASDAQ:DRTSW) Stock Price Up 14.3% – Still a Buy? - Defense World
Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Rises By 7.1% - MarketBeat
Takeout news crowns JPM’s winning stocks - biocentury.com
Alpha Tau Medical Ltd (DRTS) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):